A BILL 
To direct the Comptroller General of the United States to 
conduct a study on how direct-to-consumer pharma-
ceutical advertising negatively impacts drug costs to con-
sumers, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. GAO STUDY ON HOW DIRECT-TO-CONSUMER 
3
PHARMACEUTICAL 
ADVERTISING 
NEGA-
4
TIVELY 
IMPACTS 
DRUG 
COSTS 
TO 
CON-
5
SUMERS. 
6
(a) IN GENERAL.—Not later than 180 days after the 
7
date of the enactment of this Act, the Comptroller General 
8
19:33 Jul 26, 2021
H4278
2 
•HR 4278 IH
of the United States shall conduct a study on how direct- 
1
to-consumer pharmaceutical advertising negatively im-
2
pacts drug costs to consumers. Such study shall focus 
3
on— 
4
(1) what steps may be taken by pharmaceutical 
5
drug manufacturers and distributors to reduce the 
6
higher drug costs paid by consumers as a result of 
7
such advertising by splitting the cost of advertising 
8
between each organization developing a particular 
9
drug; 
10
(2) the expectations of consumers and patients 
11
with respect to the drugs so advertised; and 
12
(3) the role such advertisements play in pro-
13
moting medication to patients for whom such medi-
14
cation may not be necessary. 
15
(b) REPORT.—The Comptroller General shall— 
16
(1) submit a report containing the results of 
17
the study to— 
18
(A) the Committee on the Judiciary and 
19
the Committee on Energy and Commerce of the 
20
House of Representatives; and 
21
(B) the Committee on the Judiciary and 
22
the Committee on Health, Education, Labor, 
23
and Pensions of the Senate; and 
24
19:33 Jul 26, 2021
H4278
3 
•HR 4278 IH
(2) make such report publicly available. 
1
Æ 
19:33 Jul 26, 2021
H4278
